Reshaping the future of global clinical trials practice

Researchers at the University of Liverpool have developed a new international guideline to help standardise how results from clinical trial studies are reported. Use of the COS-STAR guideline, which is published in PLOS Medicine, could increase the efficiency and value of clinical research across the globe.

Every year, hundreds of thousands of members of the public are recruited into tens of thousands of clinical trials in health and social care, and thousands of researchers prepare systematic reviews to bring together the findings of existing trials.

Much of this effort can be wasted if the outcomes measured and reported are not those necessarily needed by health service users, practitioners, policy makers and others making choices between different interventions, actions and strategies.

To address these issues, a standardised set of outcomes, known as a 'core outcome set' (COS) can be used. These sets should represent the minimum that should be measured and reported in all clinical trials, audits of practice or other forms of research for a specific condition.

The credibility of a COS depends on both the use of sound methodology in its development and clear and transparent reporting of the processes adopted. However, to date there has been no guideline for reporting COS studies.

Now, an international group of researchers, led by Dr Jamie Kirkham and Professor Paula Williamson from the University of Liverpool, and made up of experienced COS developers, methodologists, journal editors, potential users of COS and patient representatives, have developed the COS-STAR (Core Outcome Set-STAndards for Reporting) Statement, which consists of a checklist of 18 items considered essential for transparent and complete reporting in all COS studies.

Professor Paula Williamson, Head of the University's Department of Biostatistics, said: "The current gap between clinical researchers, patients and other decision makers throughout the world needs to be closed.

"COS will be a key element in reshaping the future of global clinical trials practice, increasing the efficiency and value of the research process by reducing inefficiencies that arise when trials in similar areas measure the same outcomes in different ways.

"In order to realise this impact, COS studies need to be well-reported, and so the new COS-STAR guidelines will facilitate good reporting and therefore uptake."

Kirkham JJ, Gorst S, Altman DG, Blazeby JM, Clarke M, Devane D, Gargon E, Moher D, Schmitt J, Tugwell P, Tunis S, Williamson PR.
Core Outcome Set-STAndards for Reporting: The COS-STAR Statement.
PLoS Med. 2016 Oct 18;13(10):e1002148. doi: 10.1371/journal.pmed.1002148.

Most Popular Now

Pfizer begins a Phase 1/2 study to evaluate respir…

Pfizer Inc. (NYSE:PFE) today announced that it has started a Phase 1/2 trial of its respiratory syncytial virus (RSV) vaccine candidate in healthy adult volunteers. RSV i...

Eczema drug effective against severe asthma

Two new studies of patients with difficult-to-control asthma show that the eczema drug dupilumab alleviates asthma symptoms and improves patients' ability to breathe bett...

Most popular vitamin and mineral supplements provi…

The most commonly consumed vitamin and mineral supplements provide no consistent health benefit or harm, suggests a new study led by researchers at St. Michael's Hospital...

AstraZeneca heads to 2018 ASCO Annual Meeting with…

AstraZeneca and MedImmune, its global biologics research and development arm, head to the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US...

Tiny particles could help fight brain cancer

Glioblastoma multiforme, a type of brain tumor, is one of the most difficult-to-treat cancers. Only a handful of drugs are approved to treat glioblastoma, and the median ...

Novartis data at ASCO and EHA reinforce company's …

Novartis will present data from across its oncology portfolio at the upcoming 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held June 1-5 ...

Spiolto® Respimat® enables greater physical activi…

Boehringer Ingelheim announced data which add to the growing body of evidence that show Spiolto® (tiotropium/olodaterol) Respimat® enables greater physical activity in pa...

New approach to immunotherapy leads to complete re…

A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was...

Amgen Foundation and Harvard team up to offer free…

The Amgen Foundation and Harvard University today announced plans to launch a free online science education platform uniquely designed to level the playing field for aspi...

Study demonstrates new treatment for severe asthma

Researchers from McMaster University and the Firestone Institute for Respiratory Health at St. Joseph's Healthcare Hamilton, together with colleagues at other partnering ...

The Pfizer Foundation announces $5 million in gran…

The Pfizer Foundation announced a new $5 million grant commitment to initiatives in low- and middle-income countries that provide family planning access and education for...

Study finds antioxidant-enriched vitamin reduces r…

Researchers at Children's Hospital Colorado (Children's Colorado) and the University of Colorado School of Medicine have found that taking a specially formulated antioxid...